Mark Fleischman, MD
MOHS-Micrographic Surgery · Leawood, KSNPI 1215975867
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 45.9% of the total. Reporting peaked in 2024 at $13,056 and has fallen 84.6% since, to $2,005 in 2025.
Across 535 payments — averaging $43.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$11K
- AbbVie$3K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$922
- Regeneron Healthcare Solutions, Inc.$886
- Lilly USA, LLC$662
- plus $6K from 34 others
Across 103 payments — averaging $9382.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$698K
- Amgen$128K
- Sanofi US Services Inc.$56K
- Eli Lilly$45K
- E.r. Squibb & Sons, L.L.C.$25K
- Janssen Research & Development, LLC$14K
What the payments were for
- Consulting fees$7,50032%
- Speaking & faculty fees$5582%
- Travel & lodging$2,2009%
- Food & beverage$13,10256%
- Education$980%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few mohs-micrographic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 95 | $6,060 |
| Cephalexin | 833 | $4,738 |
| Doxycycline Hyclate | 359 | $2,829 |
| Ketoconazole | 205 | $2,557 |
| Gentamicin Sulfate | 94 | $2,505 |
| Metronidazole | 30 | $1,628 |
| Clobetasol Propionate | 25 | $1,461 |
| Fluocinonide | 34 | $1,066 |
| Triamcinolone Acetonide | 151 | $1,029 |
| Hydrocortisone | 160 | $838 |
| Betamethasone Dipropionate | 18 | $832 |
| Nystatin | 45 | $698 |
| ValacyclovirValacyclovir Hcl | 34 | $456 |
| Clindamycin Phosphate | 19 | $443 |
| Mupirocin | 43 | $365 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Leawood
- James GriffithLeawood$5K
- Shawn SabinLeawood$4K
- Glenn GoldsteinLeawood$2K
- Elizabeth SpenceriLeawood$2K
- Joseph GadziaTopeka$28K
- Majdy AlbahharManhattan$10K
- Matthew ShafferSalina$8K
- Kevin BroughWichita$8K
- Jeanette PittsMission$940
- Jesalyn TateKansas City$893
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.